Disease · MONDO_0005321
Trials12
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
1 to 12 of 12
Download this page as JSON| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04498169 | A Phase 2 Study Evaluating the Safety and Efficacy of Netarsudil Ophthalmic Solution in Patients With Corneal Edema Due to Fuchs Corneal Dystrophy | Phase 2 | 40 | 2022-09-01 | Corneal Edema | NETARSUDIL | Its record names the disease | ClinicalTrials.gov |
| NCT04051463 | Rhopressa for Corneal Edema Associated With Fuchs Dystrophy | Phase 2/3 | 29 | 2021-09-24 | Fuchs Endothelial Dystrophy | NETARSUDIL | Its record names the disease | ClinicalTrials.gov |
| NCT02653391 | A Study Investigating the Safety, Tolerability, and Efficacy of Elamipretide Topical Ophthalmic Solution for the Treatment of Fuchs' Corneal Endothelial Dystrophy (FCED) | Phase 1/2 | 22 | 2021-09-17 | Fuchs' Corneal Endothelial Dystrophy (FCED) | ELAMIPRETIDE | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT06048380 | The Effects of Ripasudil in Patients With FED Undergoing Femtosecond Laser Assisted Cataract Surgery | Phase 3 | 120 | Fuchs' Endothelial Dystrophy, Cataract | RIPASUDIL | Its record names the disease | ClinicalTrials.gov | |
| NCT05826353 | A Study to Investigate the Safety and Efficacy of K-321 Eye Drops After Simultaneous Cataract Surgery and Descemetorhexis in Participants With Fuchs Endothelial Corneal Dystrophy (FECD) | Phase 3 | 110 | Fuchs Endothelial Corneal Dystrophy | RIPASUDIL | Its record names the disease | ClinicalTrials.gov | |
| NCT05795699 | A Study to Evaluate the Safety and Efficacy of K-321 Eye Drops After Descemetorhexis in Participants With Fuchs Endothelial Corneal Dystrophy (FECD) | Phase 3 | 107 | Fuchs Endothelial Corneal Dystrophy | RIPASUDIL | Its record names the disease | ClinicalTrials.gov | |
| NCT03813056 | Ripasudil for Enhanced Corneal Clearing Following Descemet Membrane Endothelial Keratoplasty in Fuchs' Dystrophy | Phase 2 | 72 | Fuchs Endothelial Dystrophy | RIPASUDIL HYDROCHLORIDE DIHYDRATE | Its record names the disease | ClinicalTrials.gov | |
| NCT05275972 | Descemet Endothelial Thickness Comparison Trial II | Phase 3 | 60 | Fuchs, Fuchs Dystrophy, Fuchs' Endothelial Dystrophy | RIPASUDIL | Its record names the disease | ClinicalTrials.gov | |
| NCT06969586 | The Effect of Topical Rho-kinase Inhibitors on Corneas of Patients With Fuchs Endothelial Corneal Dystrophy | 50 | Fuchs Endothelial Corneal Dystrophy, Cataract, Glaucoma | NETARSUDIL | Its record names the disease | ClinicalTrials.gov | ||
| NCT04440280 | Targeting Reactive Oxygen Species Production as a Novel Therapeutic in Fuch's Endothelial Corneal Dystrophy | Phase 2 | 45 | Fuchs Endothelial Corneal Dystrophy | ACETYLCYSTEINE | Its record names the disease | ClinicalTrials.gov | |
| NCT03575130 | Ripasudil 0.4% Eye Drops in Fuchs Endothelial Corneal Dystrophy | Phase 2 | 21 | Fuchs' Endothelial Dystrophy, Fuchs Dystrophy, Corneal Endothelial Dystrophy, Corneal Endothelial Cell Loss, Cornea Guttata | RIPASUDIL | Its record names the disease | ClinicalTrials.gov | |
| NCT04057053 | Netarsudil Use After Descemetorhexis Without Endothelial Keratoplasty | Early phase 1 | 10 | Fuchs' Endothelial Dystrophy, Cataract | NETARSUDIL | Its record names the disease | ClinicalTrials.gov |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005321/trials